Mainstream

FibroGen outlines $185M China divestiture and extended cash runway into 2027 while advancing prostate cancer pipeline

FibroGen outlines $185M China divestiture and extended cash runway into 2027 while advancing prostate cancer pipeline

Post ContentfgenRead More

You might also be interested in reading Circle’s USDC outpaces growth of Tether’s USDT for second year running.

May 13, 2025
In Mainstream